S&P 500   4,241.68 (+0.29%)
DOW   33,032.31 (+0.09%)
QQQ   356.29 (+0.39%)
AAPL   171.57 (-0.48%)
MSFT   315.30 (+0.61%)
META   300.25 (-0.23%)
GOOGL   133.37 (+0.71%)
AMZN   125.93 (+0.97%)
TSLA   248.07 (+0.62%)
NVDA   437.44 (+0.52%)
NIO   8.56 (-0.58%)
BABA   84.32 (-0.26%)
AMD   100.55 (+0.47%)
T   14.79 (+0.07%)
F   12.08 (+0.08%)
MU   68.45 (+0.91%)
CGC   0.71 (+3.32%)
GE   108.05 (+0.27%)
DIS   79.78 (+0.30%)
AMC   7.91 (+0.76%)
PFE   33.90 (-0.12%)
PYPL   58.05 (+1.31%)
NFLX   378.51 (+0.47%)
S&P 500   4,241.68 (+0.29%)
DOW   33,032.31 (+0.09%)
QQQ   356.29 (+0.39%)
AAPL   171.57 (-0.48%)
MSFT   315.30 (+0.61%)
META   300.25 (-0.23%)
GOOGL   133.37 (+0.71%)
AMZN   125.93 (+0.97%)
TSLA   248.07 (+0.62%)
NVDA   437.44 (+0.52%)
NIO   8.56 (-0.58%)
BABA   84.32 (-0.26%)
AMD   100.55 (+0.47%)
T   14.79 (+0.07%)
F   12.08 (+0.08%)
MU   68.45 (+0.91%)
CGC   0.71 (+3.32%)
GE   108.05 (+0.27%)
DIS   79.78 (+0.30%)
AMC   7.91 (+0.76%)
PFE   33.90 (-0.12%)
PYPL   58.05 (+1.31%)
NFLX   378.51 (+0.47%)
S&P 500   4,241.68 (+0.29%)
DOW   33,032.31 (+0.09%)
QQQ   356.29 (+0.39%)
AAPL   171.57 (-0.48%)
MSFT   315.30 (+0.61%)
META   300.25 (-0.23%)
GOOGL   133.37 (+0.71%)
AMZN   125.93 (+0.97%)
TSLA   248.07 (+0.62%)
NVDA   437.44 (+0.52%)
NIO   8.56 (-0.58%)
BABA   84.32 (-0.26%)
AMD   100.55 (+0.47%)
T   14.79 (+0.07%)
F   12.08 (+0.08%)
MU   68.45 (+0.91%)
CGC   0.71 (+3.32%)
GE   108.05 (+0.27%)
DIS   79.78 (+0.30%)
AMC   7.91 (+0.76%)
PFE   33.90 (-0.12%)
PYPL   58.05 (+1.31%)
NFLX   378.51 (+0.47%)
S&P 500   4,241.68 (+0.29%)
DOW   33,032.31 (+0.09%)
QQQ   356.29 (+0.39%)
AAPL   171.57 (-0.48%)
MSFT   315.30 (+0.61%)
META   300.25 (-0.23%)
GOOGL   133.37 (+0.71%)
AMZN   125.93 (+0.97%)
TSLA   248.07 (+0.62%)
NVDA   437.44 (+0.52%)
NIO   8.56 (-0.58%)
BABA   84.32 (-0.26%)
AMD   100.55 (+0.47%)
T   14.79 (+0.07%)
F   12.08 (+0.08%)
MU   68.45 (+0.91%)
CGC   0.71 (+3.32%)
GE   108.05 (+0.27%)
DIS   79.78 (+0.30%)
AMC   7.91 (+0.76%)
PFE   33.90 (-0.12%)
PYPL   58.05 (+1.31%)
NFLX   378.51 (+0.47%)
NASDAQ:BLRX

BioLineRx (BLRX) Stock Forecast, Price & News

$1.63
+0.03 (+1.88%)
(As of 08:57 AM ET)
Compare
Today's Range
$1.63
$1.63
50-Day Range
$1.23
$2.45
52-Week Range
$0.55
$2.53
Volume
8,442 shs
Average Volume
643,658 shs
Market Capitalization
$100.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

BioLineRx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,212.5% Upside
$21.00 Price Target
Short Interest
Bearish
7.26% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of BioLineRx in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.83) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

812th out of 966 stocks

Pharmaceutical Preparations Industry

378th out of 446 stocks


BLRX stock logo

About BioLineRx (NASDAQ:BLRX) Stock

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.

BLRX Price History

BLRX Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
BLRX: …Go!
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
BioLineRx rallies on FDA approval of Aphexda with Filgrastim
BLRX: On Your Marks, Get Set…
BioLineRx GAAP EPS of -$0.02
BioLineRx (BLRX) Earnings Dates & Reports
BLRX: First Quarter Results
biolinerx Q1 2023 Earnings Preview
BioLine RX Ltd (BLRX)
See More Headlines
Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Company Calendar

Last Earnings
8/30/2023
Today
10/04/2023
Next Earnings (Estimated)
11/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLRX
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+1,212.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.83 per share

Miscellaneous

Free Float
60,854,000
Market Cap
$98.45 million
Optionable
Not Optionable
Beta
1.75
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Philip A. Serlin CPA (Age 63)
    M.B.A., CPA, MBA, Chief Exec. Officer
    Comp: $635k
  • Ms. Mali Zeevi CPA (Age 47)
    CPA, Chief Financial Officer
    Comp: $380k
  • Dr. Ella Sorani (Age 55)
    Chief Devel. Officer
    Comp: $457k
  • Ms. Holly W. May M.B.A. (Age 61)
    Pres of BioLineRx USA
    Comp: $328k
  • Mr. John Lacey
    Head of Corp. Communications & Investor Relations
  • Mr. Adam Janoff Esq.
    Gen. Counsel & Head of Compliance
  • Ms. Tsipi Keren-Lehrer B.Sc.
    L.L.B., Head of BD & Strategic Advisor
  • Mr. Raziel Fried
    Treasurer & Budgetary Control Director













BLRX Stock - Frequently Asked Questions

Should I buy or sell BioLineRx stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLRX shares.
View BLRX analyst ratings
or view top-rated stocks.

What is BioLineRx's stock price forecast for 2023?

1 Wall Street analysts have issued 1 year price targets for BioLineRx's shares. Their BLRX share price forecasts range from $21.00 to $21.00. On average, they anticipate the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 1,212.5% from the stock's current price.
View analysts price targets for BLRX
or view top-rated stocks among Wall Street analysts.

How have BLRX shares performed in 2023?

BioLineRx's stock was trading at $0.59 at the beginning of the year. Since then, BLRX shares have increased by 171.2% and is now trading at $1.60.
View the best growth stocks for 2023 here
.

Are investors shorting BioLineRx?

BioLineRx saw a increase in short interest in September. As of September 15th, there was short interest totaling 4,470,000 shares, an increase of 86.3% from the August 31st total of 2,400,000 shares. Based on an average daily trading volume, of 1,090,000 shares, the days-to-cover ratio is currently 4.1 days.
View BioLineRx's Short Interest
.

When is BioLineRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our BLRX earnings forecast
.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) released its earnings results on Wednesday, August, 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.14. During the same quarter last year, the firm posted ($0.16) EPS.

What other stocks do shareholders of BioLineRx own?
What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLineRx's stock price today?

One share of BLRX stock can currently be purchased for approximately $1.60.

How much money does BioLineRx make?

BioLineRx (NASDAQ:BLRX) has a market capitalization of $98.45 million. The biotechnology company earns $-24,950,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How can I contact BioLineRx?

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The official website for the company is www.biolinerx.com. The biotechnology company can be reached via phone at (728) 642-9100, via email at ir@biolinerx.com, or via fax at 972-8642-9101.

This page (NASDAQ:BLRX) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -